Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma

被引:36
作者
Desikan, R
Veksler, Y
Raza, S
Stokes, B
Sabir, T
Li, ZJ
Jagannath, S
机构
[1] NYU, Med Ctr, St Vincents Comprehens Canc Ctr, Myeloma & Transplantat Program, New York, NY 10011 USA
[2] NYU, Med Ctr, Dept Pathol, New York, NY 10011 USA
关键词
pamidronate; proteinuria;
D O I
10.1046/j.1365-2141.2002.03826.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Five patients receiving increased dose or frequency of pamidronate beyond the recommended dose (90 mg/monthly) exhibited nephrotic proteinuria (range 3.96-24 g/24 h). On dose reduction or discontinuation, three of these patients showed decreased proteinuria to normal levels (<1 g/24 h), and proteinuria decreased to 4.5 g/24 h from a peak of 24 g/24 h in one patient. One patient on haemodialysis (hence not evaluable) had proteinuria of 2 g/24 h and elevated creatinine levels. One other patient continued to show elevated creatinine levels (272.8 μmol/ l). Renal biopsies obtained in two patients revealed focal segmental glomerulosclerosis.
引用
收藏
页码:496 / 499
页数:4
相关论文
共 11 条
[1]   Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events [J].
Berenson, JR ;
Lichtenstein, A ;
Porter, L ;
Dimopoulos, MA ;
Bordoni, R ;
George, S ;
Lipton, A ;
Keller, A ;
Ballester, O ;
Kovacs, M ;
Blacklock, H ;
Bell, R ;
Simeone, JF ;
Reitsma, DJ ;
Heffernan, M ;
Seaman, J ;
Knight, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :593-602
[2]   Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase [J].
Bergstrom, JD ;
Bostedor, RG ;
Masarachia, PJ ;
Reszka, AA ;
Rodan, G .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 373 (01) :231-241
[3]   DISPOSITION AND NEPHROTOXICITY OF 3-AMINO-1-HYDROXYPROPYLIDENE-1,1-BISPHOSPHONATE (APD), IN RATS AND MICE [J].
CAL, JC ;
DALEYYATES, PT .
TOXICOLOGY, 1990, 65 (1-2) :179-197
[4]  
Corso A, 1999, HAEMATOLOGICA, V84, P759
[5]   Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298 [J].
Coxon, FP ;
Helfrich, MH ;
Van't Hof, R ;
Sebti, S ;
Ralston, SH ;
Hamilton, A ;
Rogers, MJ .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (08) :1467-1476
[6]   Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment [J].
Derenne, S ;
Amiot, M ;
Barillé, S ;
Collette, M ;
Robillard, N ;
Berthaud, P ;
Harousseau, JL ;
Bataille, R .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (12) :2048-2056
[7]   Anti-myeloma activity of pamidronate in vivo [J].
Dhodapkar, MV ;
Singh, J ;
Mehta, J ;
Fassas, A ;
Desikan, KR ;
Perlman, M ;
Munshi, NC ;
Barlogie, B .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (02) :530-532
[8]  
Kunzmann V, 2000, BLOOD, V96, P384
[9]  
Markowitz GS, 2001, J AM SOC NEPHROL, V12, P1164, DOI 10.1681/ASN.V1261164
[10]   Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity [J].
Shipman, CM ;
Rogers, MJ ;
Apperley, JF ;
Graham, R ;
Russell, G ;
Croucher, PI .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (03) :665-672